Johnson & Johnson (NYSE:JNJ) is Talisman Wealth Advisors LLC’s 9th Largest Position

Posted by Defense World Staff on Aug 28th, 2023

Talisman Wealth Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 11.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,305 shares of the company’s stock after purchasing an additional 979 shares during the quarter. Johnson & Johnson accounts for 2.6% of Talisman Wealth Advisors LLC’s investment portfolio, making the stock its 9th biggest position. Talisman Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. GW&K Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $35,000. Dark Forest Capital Management LP boosted its holdings in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $42,000. Kepos Capital LP acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $45,000. Finally, 25 LLC bought a new stake in shares of Johnson & Johnson in the first quarter worth $55,000. 68.40% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $166.25 on Monday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The stock has a fifty day moving average price of $166.68 and a two-hundred day moving average price of $161.48. The firm has a market cap of $432.08 billion, a P/E ratio of 33.65, a PEG ratio of 2.79 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same quarter in the previous year, the business posted $2.59 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.86%. Johnson & Johnson’s payout ratio is presently 96.36%.

Insiders Place Their Bets

In related news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 over the last ninety days. 0.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, August 17th. They issued a “strong-buy” rating on the stock. Credit Suisse Group upped their price target on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Finally, Atlantic Securities lifted their target price on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $171.80.

Check Out Our Latest Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.